Trondheim based Vitroscope announced a USD 5 million seed round on 3 November 2026, co led by Cerberus Ventures and YZR Capital. Arcas Ventures, Golden Egg Check, Devico Invest and several angels also participated. The company separately secured USD 2 million in non dilutive funding from the Research Council of Norway. Vitroscope develops perfusion systems that keep living human tissue under controlled flow, oxygen and temperature conditions for longer experiments. The equity funding will support commercial rollout of its vitro.alive benchtop platform and validation of vitro.scale, a higher throughput system planned for customer testing in 2027.
Vitroscope raises USD 5m seed round
Separate grant funding supports live tissue drug research platform

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


